Boston Scientific to acquire Penumbra in $14.5 billion deal
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
Subscribe To Our Newsletter & Stay Updated